We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Lithium (low-dose / pharmacological)
An element and mood-stabilizer drug studied at low doses as a geroprotector and neuroprotectant. Intriguing signals — drinking-water epidemiology links trace lithium to lower mortality and dementia, and it extends lifespan in worms — but human evidence is associational, model-organism results are mixed, and therapeutic lithium has a narrow safety window. A prescription drug used off-label; the OTC microdose form is lithium orotate.
Prescription medication — not a dietary supplement
Lithium (low-dose) is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Lithium (low-dose) doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 1968–2026.
Based on 285 studies · 37 meta-analyses · 211 RCTs
Confidence
High confidenceBy outcome
Low-dose lithium has a robust neuroprotective mechanism (GSK-3 inhibition, autophagy, BDNF) and suggestive drinking-water epidemiology linking it to lower mortality and dementia, but the human evidence is associational, model-organism lifespan results are mixed/sex-dependent, and therapeutic lithium has a narrow safety window — so the geroprotector case is intriguing but unproven.
206 randomised trials
every one checked individually
Every randomised or controlled trial of Lithium (low-dose) indexed in PubMed, not a hand-picked subset. Meta-analyses and systematic reviews are deliberately excluded from this count: most of them cover many compounds at once, so counting them would inflate it.
PubMed · as of Jul 2026
No trials currently enrolling · 11 completed on ClinicalTrials.gov
6 of the completed trials have posted results
Registered trials show research momentum for Lithium (low-dose), not proof of effect — a registration is a plan, and posted results are sponsor-reported, not peer-reviewed. They are never counted toward the evidence rating above.
Browse these trials on ClinicalTrials.govClinicalTrials.gov · as of Nov 2026
Lithium is a trace element and the long-standing gold-standard drug for bipolar disorder (as lithium carbonate). Its geroscience interest comes from several converging but soft lines of evidence.
Mechanistically, lithium inhibits glycogen synthase kinase-3 (GSK-3) and inositol monophosphatase, enhances autophagy, boosts neurotrophic signaling (BDNF), and is broadly neuroprotective across cell, tissue, and animal models — pathways highly relevant to brain aging and neurodegeneration.
Epidemiologically, the influential Zarse 2011 analysis found that regions with higher trace lithium in drinking water had lower all-cause mortality, and that low-dose lithium extended lifespan in the worm C. elegans; subsequent population studies have repeatedly (though not uniformly) linked higher drinking-water lithium to lower dementia incidence.
Small human trials of low-dose lithium in mild cognitive impairment and Alzheimer's disease suggest cognitive stabilization and biomarker effects, and a recent pilot randomized trial in MCI examined its feasibility, safety, and preliminary efficacy.
The honest picture is that none of this is proof of human longevity: the drinking-water data are observational and confounded, the model-organism lifespan results are mixed (lithium's effect in Drosophila is dose- and sex-dependent and can reduce the female lifespan advantage), and the human cognitive trials are small and preliminary.
Safety is the other key caveat: at therapeutic (bipolar) doses lithium has a narrow window with real toxicity — thyroid suppression, kidney effects, tremor, and dangerous toxicity in overdose or dehydration — so longevity interest centers on much lower 'microdoses,' which are far safer but also far less proven.
The OTC microdose form sold as a supplement is lithium orotate (covered separately); the evidence here is for pharmacological/low-dose lithium used off-label for neuroprotection/longevity.
The score reflects a strong neuroprotective mechanism and suggestive epidemiology against associational-only human data, mixed animal results, and a narrow therapeutic-dose safety window.
Lithium inhibits glycogen synthase kinase-3, a kinase central to tau phosphorylation, circadian and metabolic signaling — a key proposed neuroprotective/anti-aging mechanism.
By inhibiting inositol monophosphatase and lowering inositol, lithium induces autophagy, clearing aggregated proteins implicated in neurodegeneration.
Lithium raises BDNF and pro-survival signaling and is neuroprotective across many models — the basis of its dementia and longevity interest.
How Lithium (low-dose) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Therapeutic lithium carries a cardiac-malformation risk; use only under specialist guidance.
Lithium passes into breast milk and infant serum levels can approach maternal ones. Breastfeeding on therapeutic lithium is a decision for the specialist who prescribed it, with infant monitoring, and needs extra caution with a preterm or newborn infant. Any change to the dose or to feeding is theirs to make.
High toxicity risk — avoid or monitor closely at therapeutic doses.
Much lower risk, but evidence is weaker; see the lithium-orotate entry.
Reduce lithium clearance and can raise levels into the toxic range — a classic, dangerous interaction at therapeutic doses.
Raise lithium concentration and toxicity risk.
Tip: Dose-related; far less likely at microdoses.
Tip: Monitor thyroid on longer/therapeutic use.
Tip: Therapeutic dosing requires blood-level and renal monitoring; toxicity is a medical emergency.
Lithium (low-dose) has an evidence score of 3/10 — emerging evidence based on 285 indexed studies. An element and mood-stabilizer drug studied at low doses as a geroprotector and neuroprotectant. Intriguing signals — drinking-water epidemiology links trace lithium to lower mortality and dementia, and it extends lifespan in worms — but human evidence is associational, model-organism results are mixed, and therapeutic lithium has a narrow safety window. A prescription drug used off-label; the OTC microdose form is lithium orotate. Representative study: PMID 39212809.
Dosing for Lithium (low-dose): Geroprotective interest centers on LOW doses far below bipolar dosing. The OTC microdose form is lithium orotate (~1–5 mg elemental lithium; see that supplement). Therapeutic lithium carbonate (hundreds of mg, blood-level-monitored) is a different, higher-risk regimen used for bipolar disorder under a clinician. No validated longevity dose exists. (no cited human trial states a dose). Individual needs vary, so check the right dose for you with a healthcare provider.
Timing is flexible for Lithium (low-dose) — consistent daily use matters more than the time of day. Take with food/water to limit GI upset; stay hydrated (dehydration raises lithium levels).
Lithium (low-dose) should be used with caution — talk to a healthcare provider before taking it. Reported side effects include kidney effects / lithium toxicity, thyroid suppression (hypothyroidism), tremor / GI upset. How often they occur is not established for all of them. Use caution if any of these apply to you: Significant renal impairment; Dehydration / significant sodium depletion; Pregnancy (cardiac malformation risk at therapeutic doses).
CoQ10
Likely helpsA lipid-soluble antioxidant central to mitochondrial energy production, with the strongest trial support for fertility/IVF outcomes and heart failure.
Huperzine A
Too few graded studiesAcetylcholinesterase inhibitor from club moss, studied mainly for Alzheimer's and dementia; cognitive evidence is mixed and limited by trial quality.
Pregnenolone
Likely helpsA steroid-hormone precursor and neurosteroid being studied mainly in clinical psychiatry; human evidence is early and there is no proven benefit for cognition, mood, or anti-aging in healthy people.
Luteolin
Too few graded studiesA dietary flavonoid with anti-inflammatory effects in the lab. The honest verdict: the only direct human RCTs test PEA-luteolin combinations for post-COVID smell loss — isolated luteolin's anti-inflammatory, allergy, and brain claims rest on mechanism and reviews, not human trials, and its bioavailability is low.
Explore: Best supplements for Vitality & LongevityBest supplements for Focus, Memory & Mood
Reviewed by Dr. Baher Al Hakim · Last reviewed June 2026 · evidence from 285 studies · how we score · editorial policy
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Tap node to isolate • Pinch to zoom • Tap edge for research